Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer
NCT ID: NCT00547612
Last Updated: 2012-03-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
33 participants
INTERVENTIONAL
2007-09-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase I trial is studying how well a PET scan using \[18F\]-labeled substance P antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07217717
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
NCT00735917
In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer
NCT03492164
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT04172532
R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer
NCT00005843
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine whether \[18F\]-labeled substance P antagonist receptor quantifier positron emission tomography can identify pancreatic cancer evident on multiphase CT scan.
OUTLINE: Patients undergo multiphase CT scan of the chest, abdomen, and pelvis. No more than 15 days later, patients receive \[18F\]-labeled substance P antagonist receptor quantifier IV and undergo positron emission tomography over 6 hours.
Blood is collected periodically to measure the metabolism of the radiotracer by high performance liquid chromatography with radioactive detectors.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
DIAGNOSTIC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
high performance liquid chromatography
pharmacological study
[18F]-labeled substance P antagonist receptor quantifier
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* WBC ≥ 1,200/mm³
* Creatinine \< 2.0 mg/dL
* Negative pregnancy test
* Fertile patients must agree to use effective contraception
* Not pregnant or nursing
* More than 4 weeks since prior abdominal surgery
Exclusion Criteria
* Claustrophobia that would preclude completion of a scan or unable to lie on one's back for positron emission tomography scan
PRIOR CONCURRENT THERAPY:
* Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits
* Aprepitant within 72 hours of \[18F\]-labeled substance P antagonist receptor quantifier positron emission tomography
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
National Institutes of Health Clinical Center (CC)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard E. Royal, MD, FACS
Role: STUDY_CHAIR
NCI - Surgery Branch
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-C-0222
Identifier Type: -
Identifier Source: secondary_id
CDR0000570181
Identifier Type: -
Identifier Source: secondary_id
070222
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.